Post Conference Insight: The European Cancer Congress 2013.
By Colin White, Lead Analyst
2 October 2013
I am the Lead Analyst for Oncology at Datamonitor Healthcare. I joined Datamonitor in 2009, having previously worked as ...
Read full bio
Datamonitor Healthcare attended the 2013 European Cancer Congress (ECCO 17-ESMO 38-ESTRO 32) which took place between 27 September and 1 October in Amsterdam, Netherlands.
Download the full white paper using the adjacent form >>
Datamonitor Healthcare has identified the following key highlights from the meeting:
Results from Kadcyla Phase III Tiral, TH3RESA, and the impact this will have on the breast cancer market
Coverage on the anti-programmed death 1 (PD-1) and PD-L1 agents. Bristol-Myers Squibb, Merck & Co, and Roche continue to compete to gain the coveted first-to-market status for this new wave of immunotherapies.
Insight into BioMarin’s PARP inhibitor BMN-763 and it’s effectiveness for BRCA mutation-positive metastatic breast cancer patients
Find out the likelihood of trebananib/paclitaxel regimen being approved
Download the remainder of this White Paper using the adjacent form >>
Posted in Oncology.